stonks4u
Sign up free
ORIC logo

ORIC ORIC Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$13.87
+0.15 (+1.09%)

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candida…

Market Cap: $1.44Bwww.oricpharma.com

Price (90d)

$13.50
$7.50$9.50$11.50$13.50
Apr 29Aug 7

Signal Score (90d)

100
100
Aug 7Aug 7

Quote

Day Range
$13.42 – $13.89
52-Week Range
$7.23 – $14.93
Volume
$801.1K
Market Cap
$1.44B
50-Day Avg
$10.63
200-Day Avg
$10.59
Prev Close
$13.72
Open
$13.63

Valuation & Ratios

P/E Ratio
-5.56
EPS
$-1.47
P/B Ratio
1.87
P/S Ratio
0.00
Debt/Equity
0.03
Current Ratio
14.13
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-33.7%
Return on Assets
-31.5%
FCF Yield
-15.9%
EV/EBITDA
-5.33

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-129.47M$-1.47
2024$0.00$-127.85M$-1.83
2023$0.00$-100.70M$-1.96
2022$0.00$-89.12M$-2.25
2021$0.00$-78.72M$-2.07

Social Signal Score

50
5d
—
30d
50
1 mentions
+25.8%
60d
50
1 mentions
+62.5%
90d
50
1 mentions
+65.6%
news: 1

Earnings

Thu, Nov 12(in 3 months)

Consensus estimate $-0.40 per share

4of 7 quarters beat consensus

Typical surprise +1.9% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 3$-0.38 vs $-0.36miss
  • Mon, May 4$-0.34 vs $-0.32miss
  • Mon, Feb 23$-0.30 vs $-0.34beat
  • Thu, Nov 13$-0.33 vs $-0.41beat
  • Tue, Aug 12$-0.47 vs $-0.46miss
  • Mon, May 5$-0.42 vs $-0.51beat

Estimates and results for ORIC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ORIChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·7d ago·Neutral

    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 3, 2026 (the “Grant Date”), ORIC granted a total of 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive

    View source ↗